Delirium in the NICU: Risk or Reality?

Area of Science:

• Neonatal Intensive Care Unit (NICU) care
• Pediatric critical care
• Neuroscience

Background:

• Delirium is a common, serious complication in critically ill adults and children.
• Limited data exists on delirium incidence, risk, symptoms, and treatment specifically in the NICU population.
• Existing pediatric studies often include infants, highlighting a gap in NICU-specific research.

Purpose of the Study:

• To review the current understanding of delirium in the NICU.
• To discuss diagnostic tools and treatment strategies for NICU delirium.
• To identify areas for future research in NICU delirium.

Main Methods:

• Review of existing literature on pediatric delirium, including studies with neonatal and infant populations.
• Validation of the Cornell Assessment of Pediatric Delirium tool for neonatal and infant populations.
• Analysis of pharmacologic and non-pharmacologic treatment approaches for delirium.

Main Results:

• The Cornell Assessment of Pediatric Delirium is validated for neonatal and infant use.
• Initial delirium management involves identifying and reversing the underlying cause.
• Pharmacologic treatment is reserved for persistent or severe symptoms; routine IV haloperidol is discouraged due to adverse effects.
• Atypical antipsychotics (olanzapine, quetiapine, risperidone) show efficacy with fewer side effects; risperidone is a favorable option due to dosing and formulation.

Conclusions:

• Delirium is an underrecognized issue in the NICU requiring further investigation.
• A targeted approach to diagnosis and treatment, prioritizing cause reversal and judicious pharmacotherapy, is recommended.
• Further research involving large NICU cohorts is essential to establish optimal screening and treatment protocols.